{"title":"2025年世界肺癌大会","authors":"David Collingridge","doi":"10.1016/s1470-2045(25)00548-0","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>ARROS-1 study: new ROS1 TKI</h2>Speaking on behalf of a large international group of researchers, Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) showed that zidesamtinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), has clinically meaningful activity in patients with CNS disease, with ROS1 G2032R mutations, or in those who have exhausted all other available treatment options. In a large phase 1/2 trial, 432 patients were recruited. 50% of patients had received previous ROS1 TKIs</section></section><section><section><h2>NADIM ADJUVANT trial</h2>Interim results from a Spanish phase 3 trial suggest adjuvant chemo-immunotherapy reduces recurrence in patients with completely resected stage IB–IIIA non-small-cell lung cancer (NSCLC) and has an acceptable safety profile, according to Mariano Provencio (Universidad Autónoma de Madrid, Madrid, Spain). 206 patients from 30 hospitals in Spain were randomly assigned to receive either adjuvant chemotherapy (carboplatin plus paclitaxel) followed by observation or to the same chemotherapy plus</section></section><section><section><h2>Best screening age for lung cancer?</h2>The UK Lung Cancer Screening programme screens people up to 74 years of age. Other countries have different age limits. Given more cancers are detected at older age, Patrick Goodley (University of Manchester, Manchester, UK) and colleagues did a study to look at the trade-offs of extending the upper age limit for screening. Using data from the Yorkshire Lung Screening Trial and the North & East Manchester Lung Health Check programme, 574 cases of lung cancer were diagnosed: 384 in a 55–74 years</section></section><section><section><h2>Tobacco, radon, and air pollution</h2>Effective population-based lung cancer screening relies on increasing cost-effectiveness, improving risk stratification to identify high-risk individuals, and better understanding of the disease aetiology. Data from <18 000 participants enrolled into two screening programmes, show a potential role for polygenic risk scores (PRS) and ambient air pollution, specifically exposure to PM<sub>2·5</sub>. Lianne Trap (Erasmus University Medical Centre, Rotterdam, the Netherlands), on behalf of Dutch and Belgian</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2025 World Conference on Lung Cancer\",\"authors\":\"David Collingridge\",\"doi\":\"10.1016/s1470-2045(25)00548-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>ARROS-1 study: new ROS1 TKI</h2>Speaking on behalf of a large international group of researchers, Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) showed that zidesamtinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), has clinically meaningful activity in patients with CNS disease, with ROS1 G2032R mutations, or in those who have exhausted all other available treatment options. In a large phase 1/2 trial, 432 patients were recruited. 50% of patients had received previous ROS1 TKIs</section></section><section><section><h2>NADIM ADJUVANT trial</h2>Interim results from a Spanish phase 3 trial suggest adjuvant chemo-immunotherapy reduces recurrence in patients with completely resected stage IB–IIIA non-small-cell lung cancer (NSCLC) and has an acceptable safety profile, according to Mariano Provencio (Universidad Autónoma de Madrid, Madrid, Spain). 206 patients from 30 hospitals in Spain were randomly assigned to receive either adjuvant chemotherapy (carboplatin plus paclitaxel) followed by observation or to the same chemotherapy plus</section></section><section><section><h2>Best screening age for lung cancer?</h2>The UK Lung Cancer Screening programme screens people up to 74 years of age. Other countries have different age limits. Given more cancers are detected at older age, Patrick Goodley (University of Manchester, Manchester, UK) and colleagues did a study to look at the trade-offs of extending the upper age limit for screening. Using data from the Yorkshire Lung Screening Trial and the North & East Manchester Lung Health Check programme, 574 cases of lung cancer were diagnosed: 384 in a 55–74 years</section></section><section><section><h2>Tobacco, radon, and air pollution</h2>Effective population-based lung cancer screening relies on increasing cost-effectiveness, improving risk stratification to identify high-risk individuals, and better understanding of the disease aetiology. Data from <18 000 participants enrolled into two screening programmes, show a potential role for polygenic risk scores (PRS) and ambient air pollution, specifically exposure to PM<sub>2·5</sub>. Lianne Trap (Erasmus University Medical Centre, Rotterdam, the Netherlands), on behalf of Dutch and Belgian</section></section>\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(25)00548-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00548-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Alexander Drilon （Memorial Sloan Kettering Cancer Center, new York， NY， USA）代表一个大型国际研究小组表明，新一代ROS1酪氨酸激酶抑制剂（TKI） zidesamtinib对中枢神经系统疾病、ROS1 G2032R突变患者或已穷除所有其他可用治疗方案的患者具有临床意义的活性。在一项大型1/2期试验中，招募了432名患者。根据Mariano Provencio （universsidad Autónoma de Madrid, Spain）的研究，西班牙一项3期试验的中期结果表明，辅助化疗免疫治疗可减少完全切除的IB-IIIA期非小细胞肺癌（NSCLC）患者的复发，并且具有可接受的安全性。来自西班牙30家医院的206名患者被随机分配接受辅助化疗（卡铂+紫杉醇）观察，或接受相同的化疗+肺癌的最佳筛查年龄？英国肺癌筛查项目对74岁以下的人进行筛查。其他国家有不同的年龄限制。鉴于更多的癌症是在老年人中被发现的，Patrick Goodley（曼彻斯特大学，曼彻斯特，英国）和他的同事做了一项研究，看看延长筛查年龄上限的权衡。使用来自约克郡肺部筛查试验和北、东曼彻斯特肺部健康检查项目的数据，574例肺癌被诊断出来：其中384例在55-74岁之间。烟草、氡和空气污染。有效的基于人群的肺癌筛查依赖于提高成本效益，改善风险分层以识别高风险个体，以及更好地了解疾病的病因。来自18,000名参加了两个筛查项目的参与者的数据显示，多基因风险评分（PRS）和环境空气污染，特别是暴露于pmm2·5的潜在作用。Lianne Trap（荷兰鹿特丹伊拉斯谟大学医学中心），代表荷兰和比利时发言
Speaking on behalf of a large international group of researchers, Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) showed that zidesamtinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), has clinically meaningful activity in patients with CNS disease, with ROS1 G2032R mutations, or in those who have exhausted all other available treatment options. In a large phase 1/2 trial, 432 patients were recruited. 50% of patients had received previous ROS1 TKIs
NADIM ADJUVANT trial
Interim results from a Spanish phase 3 trial suggest adjuvant chemo-immunotherapy reduces recurrence in patients with completely resected stage IB–IIIA non-small-cell lung cancer (NSCLC) and has an acceptable safety profile, according to Mariano Provencio (Universidad Autónoma de Madrid, Madrid, Spain). 206 patients from 30 hospitals in Spain were randomly assigned to receive either adjuvant chemotherapy (carboplatin plus paclitaxel) followed by observation or to the same chemotherapy plus
Best screening age for lung cancer?
The UK Lung Cancer Screening programme screens people up to 74 years of age. Other countries have different age limits. Given more cancers are detected at older age, Patrick Goodley (University of Manchester, Manchester, UK) and colleagues did a study to look at the trade-offs of extending the upper age limit for screening. Using data from the Yorkshire Lung Screening Trial and the North & East Manchester Lung Health Check programme, 574 cases of lung cancer were diagnosed: 384 in a 55–74 years
Tobacco, radon, and air pollution
Effective population-based lung cancer screening relies on increasing cost-effectiveness, improving risk stratification to identify high-risk individuals, and better understanding of the disease aetiology. Data from <18 000 participants enrolled into two screening programmes, show a potential role for polygenic risk scores (PRS) and ambient air pollution, specifically exposure to PM2·5. Lianne Trap (Erasmus University Medical Centre, Rotterdam, the Netherlands), on behalf of Dutch and Belgian
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
